Breast Cancer Research and Treatment

Papers
(The TQCC of Breast Cancer Research and Treatment is 8. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Intraoperative assessment of axillary sentinel lymph nodes by telepathology101
Differential response of luminal and basal breast cancer cells to acute and chronic hypoxia91
Comparative efficacy and safety of extended adjuvant endocrine therapy for hormone receptor-positive early breast cancer: a Bayesian network meta-analysis88
Correction: Timely cancer genetic counseling and testing for young women with breast cancer: impact on surgical decision-making for contralateral risk-reducing mastectomy74
Uncovering novel pathogenic variants and pathway mutations in triple-negative breast cancer among the endogamous mizo tribe62
Temporal patterns of breast cancer incidence, mortality, disability-adjusted life years and risk factors in 12 South American Countries, 1990–2019: an examination using estimates from the global burde61
The feasibility and safety of fasting-mimicking diet in breast cancer patients with chemotherapy in China57
Area deprivation index and breast cancer outcomes among patients in Western New York55
Therapeutic impact of 18F-FDG PET/CT for initial staging in patients with clinical stage I and IIA, HER2-positive, or triple-negative breast cancer47
Cognitive effects of aromatase inhibitors in early breast cancer patients: a prospective study46
Omission of anthracyclines from neoadjuvant chemotherapy for breast cancer: a population-based analysis45
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer44
Neoadjuvant docetaxel, epirubicin, and cyclophosphamide with or without metformin in breast cancer patients with metabolic abnormality: results from the randomized Phase II NeoMET trial43
Outcomes of male patients with HR+/HER2– advanced breast cancer receiving palbociclib in the real-world POLARIS study42
Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival37
Premenopausal women with breast cancer in the early post-partum period show molecular profiles of invasion and are associated with poor prognosis36
The association between cirrhosis and outcomes among female patients undergoing surgery for breast cancer in Ontario: a population-based study34
Oncotype DX recurrence score in node-positive patients in the post-RxPONDER era: a single-institution experience33
Predicting the likelihood of carrying BRCA1 or BRCA2 pathogenic variants in high-risk Pakistani breast cancer patients32
Outcomes after treatment of breast cancer during pregnancy including taxanes and/or granulocyte colony-stimulating factor use: findings from a multi-institutional retrospective analysis31
Impact of pembrolizumab on ovarian function in young triple-negative breast cancer patients treated with chemo-immunotherapy31
Using Oncotype DX breast recurrence score® assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer31
Integrating SENOMAC and AMAROS: a call for de-escalation31
Long-term dietary intervention influence on physical activity in the Women’s Health Initiative Dietary Modification randomized trial30
Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study30
Chronic inflammatory diseases and survival among breast cancer patients in the U.S. military health system28
Endocrine adherence in male versus female breast cancer: a seer-medicare review27
A phase I/II study of preoperative letrozole, everolimus, and carotuximab in stage 2 and 3 hormone receptor-positive and Her2-negative breast cancer27
Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy27
Pruritus related to trastuzumab and pertuzumab in HER2 + breast cancer patients27
Assessing the accuracy of inflammatory breast cancer self-reported diagnoses through the metastatic breast cancer project from the count me in initiative database26
Surveillance mammography after treatment for male breast cancer26
Inter-reader agreement of breast magnetic resonance imaging and contrast-enhanced mammography in breast cancer diagnosis: a multi-reader retrospective study26
Cardiovascular adverse events associated with denosumab versus zoledronic acid in patients with breast cancer: a propensity score overlap weighted analysis25
Prognostic and predictive impact of NOTCH1 in early breast cancer25
Nuclear magnetic resonance-determined lipoprotein profile and risk of breast cancer: a Mendelian randomization study25
Immune cells are increased in normal breast tissues of BRCA1/2 mutation carriers25
Effect of metformin and lifestyle intervention on adipokines and hormones in breast cancer survivors: a pooled analysis from two randomized controlled trials24
Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics24
SGLT1 as an adverse prognostic factor in invasive ductal carcinoma of the breast24
Correction to: Pathogenic variants among females with breast cancer and a non‑breast cancer reveal opportunities for cancer interception24
Exploring the intersectionality of race/ethnicity with rurality on breast cancer outcomes: SEER analysis, 2000–201624
Letter to the Editor in response to paper “BRCA1 promoter methylation in triple-negative breast cancer……” by K Daster et al24
Unveiling the role of PANoptosis-related genes in breast cancer: an integrated study by multi-omics analysis and machine learning algorithms23
Ocular adverse events of perioperative adjuvant docetaxel vs paclitaxel for breast cancer: propensity-score overlap-weighted analysis23
Correction: Taxane/anthracycline combinations reduced incidence of breast cancer recurrence in young women across molecular subtypes: a real-world evidence of Taiwan from 2011 to 201923
Hormone-associated dietary patterns and premenopausal breast cancer risk23
Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients22
Germline pathogenic variants associated with triple-negative breast cancer in US Hispanic and Guatemalan women using hospital and community-based recruitment strategies22
Prognosis of local invasive relapses after carcinoma in situ of the breast: a retrospective study from a population-based registry22
Sentinel lymph node biopsy before and after neoadjuvant chemotherapy in cN0 breast cancer patients: impact on axillary morbidity and survival—a propensity score cohort study21
Gaps in completion and timeliness of breast surgery and adjuvant therapy: a retrospective cohort of Haitian patients with nonmetastatic breast cancer21
Identifying gene expression predictive of response to neoadjuvant endocrine therapy in early breast cancer21
Chemotherapy for ipsilateral breast tumor recurrence: a propensity score-matching study21
Perceptions of patients and medical oncologists toward biospecimen donation in the setting of abnormal breast imaging findings20
PD-L1 22C3 CPS in paired primary breast cancer and lung metastasis20
Racial and ethnic disparities in the refusal of surgical treatment in women 40 years and older with breast cancer in the USA between 2010 and 201720
Enhancing surgical precision: active marker localization at the time of biopsy in breast cancer management20
Long-term effects of aromatase inhibitor withdrawal on bone mineral density in early breast cancer patients: 10-year follow-up results of the BREX study19
Neoadjuvant HER2-targeted regimens with or without anthracyclines for HER2-positive inflammatory breast cancer: a multicenter retrospective study19
Clinical trials of immunotherapy in triple-negative breast cancer19
Neoadjuvant therapy with doxorubicin-cyclophosphamide followed by weekly paclitaxel in early breast cancer: a retrospective analysis of 200 consecutive patients treated in a single center with a media19
Risk factors for postoperative bleeding following breast cancer surgery: a systematic review and meta-analysis19
A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets for breast cancer19
Restoring microRNA-34a overcomes acquired drug resistance and disease progression in human breast cancer cell lines via suppressing the ABCC1 gene19
Synthesis and evaluation of naphthalene derivatives as potent STAT3 inhibitors and agents against triple-negative breast cancer growth and metastasis19
A novel long non-coding RNA regulates the integrin, ITGA2 in breast cancer19
Prediction of nipple involvement in breast cancer after neoadjuvant chemotherapy: Should we rely on breast MRI to preserve the nipple?19
Rates of price disclosure associated with the surgical treatment of early-stage breast cancer one year after implementation of federal regulations19
Long-term outcomes of women with large DCIS lesions treated with breast-conserving therapy19
Validation of a breast cancer risk prediction model based on the key risk factors: family history, mammographic density and polygenic risk19
Induction of SGK1 via glucocorticoid-influenced clinical outcome of triple-negative breast cancer patients19
A retrospective study evaluating the impact of scattering radiation from imaging procedures on oocyte quality during ovarian stimulation for fertility preservation in young breast cancer patients19
Changes in breast cancer treatment during the COVID-19 pandemic: a Dutch population-based study19
Relationship between tamoxifen and cataracts: a nationwide cohort study of women in South Korea19
Real-world neoadjuvant and adjuvant Trastuzumab-containing regimen patterns and their association with survival among patients with operable HER2-positive breast cancer from 2007 to 202118
Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial18
Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study18
Clinical and sociodemographic determinants of older breast cancer survivors’ reports of receiving advice about exercise18
Prospective validation of the prognostic and predictive impact of uPA/PAI-1 in early breast cancer18
Is weight gain preventable in women with early breast cancer undergoing chemotherapy? A real-world study on dietary pattern, physical activity, and body weight before and after chemotherapy18
Alterations in the expression of homologous recombination repair (HRR) genes in breast cancer tissues considering germline BRCA1/2 mutation status18
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study18
Omission of multimodal therapy in older adults with high-risk breast cancer18
Correlation analysis between shear-wave elastography and pathological profiles in breast cancer18
Prognostic effect of nodal status before and after neoadjuvant chemotherapy in breast cancer: a Dutch population-based study18
Diagnostic value of core needle biopsy for determining HER2 status in breast cancer, especially in the HER2-low population18
A direct comparison of classical oral Navelbine vs metronomic Navelbine in metastatic breast cancer: results from the Danish Breast Cancer Group’s (DBCG) NAME-trial18
Correction: Is the CTS5 a helpful decision-making tool in the extended adjuvant therapy setting?18
Patient characteristics, treatment patterns, and outcomes of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer patients prescribed cyclin-dependent ki18
Personalized multifactorial risk assessment in neoadjuvant-treated breast carcinoma18
Social inequalities in the use of physiotherapy in women diagnosed with breast cancer in Barcelona: DAMA cohort17
Strict definition of a small tumor in breast cancer should be revisited17
Side effects and adherence trajectories of adjuvant endocrine therapy in breast cancer patients: results from the VICAN2 study17
Impact of public vs. private insurance coverage on quality of life of women with early-stage estrogen receptor-positive breast cancer17
Multi-omics portrait of ductal carcinoma in situ in young women17
Preferences of patients with high-risk HR + /HER2- breast cancer for adjuvant endocrine treatment: an adaptive choice-based conjoint analysis study from Germany16
Patient-reported outcomes after immediate and delayed DIEP-flap breast reconstruction in the setting of post-mastectomy radiation therapy—results of the multicenter UMBRELLA breast cancer cohort16
Considerations for hereditary breast and ovarian cancer syndrome molecular diagnosis: experience from the clinical practice16
Longitudinal monitoring of circulating tumor DNA to detect relapse early and predict outcome in early breast cancer16
Prognostic significance of abdominal obesity and its post-diagnosis change in a Chinese breast cancer cohort16
Preventing taxane-related peripheral neuropathy, pain and nail toxicity: a prospective self-controlled trial comparing hilotherapy with frozen gloves in early breast cancer16
Secretory breast carcinoma: clinicopathological features and prognosis of 52 patients16
Utilization of weight management treatment and subsequent cardiovascular events among patients with breast cancer16
Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer16
Treatment patterns and outcomes associated with sequential and non-sequential use of CDK4 & 6 inhibitors in patients with HR+, HER2− MBC in the real world16
Double-negative T cells with a distinct transcriptomic profile are abundant in the peripheral blood of patients with breast cancer16
Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis16
HLA gene polymorphism is a modifier of age-related breast cancer penetrance in carriers of BRCA1 pathogenic alleles15
A phase 1 study of veliparib (ABT-888) plus weekly carboplatin and paclitaxel in advanced solid malignancies, with an expansion cohort in triple negative breast cancer (TNBC) (ETCTN 8620)15
Insulin resistance and the development of breast cancer in premenopausal women: the Kangbuk Samsung Health Study15
Development of a novel prediction model for carriage of BRCA1/2 pathogenic variant in Japanese patients with breast cancer based on Japanese organization of hereditary breast and ovarian cancer regist15
Male breast cancer: a multicenter study to provide a guide for proper management15
Digital mammography and digital breast tomosynthesis for detecting invasive lobular and ductal carcinoma15
Adjuvant endocrine therapy non-initiation and non-persistence in young women with early-stage breast cancer15
Influence of tumour grade on disease survival in male breast cancer patients: a systematic review15
Cholesterol and breast cancer risk: a cohort study using health insurance claims and health checkup databases15
Association between body mass index and outcomes after autologous breast reconstruction: a nationwide inpatient database study in Japan15
Superficial and functional imaging of the tricipital lymphatic pathway: a modern reintroduction15
Dual targeting of HSP90 and BCL-2 in breast cancer cells using inhibitors BIIB021 and ABT-26315
A novel role of IGFBP5 in the migration, invasion and spheroids formation induced by IGF-I and insulin in MCF-7 breast cancer cells15
Tumor infiltrating lymphocytes and change in tumor load on MRI to assess response and prognosis after neoadjuvant chemotherapy in breast cancer15
APX2009 sensitizes hypoxic breast cancer cells to doxorubicin by increasing its accumulation and caspase-3/7-mediated apoptosis15
Survival outcomes after pathologic complete response with neoadjuvant endocrine therapy vs. neoadjuvant chemotherapy: a retrospective national database study14
A mixed method study of medical oncologists’ perceived barriers and motivators to addressing long-term effects in breast cancer survivors14
BRCAness of brain lesions reflects a worse outcome for patients with metastatic breast cancer14
Influence of rurality on lymph node assessment among women diagnosed with ductal carcinoma in situ and treated with mastectomy, SEER 2000–201514
Changes in the survival of patients with breast cancer: Poland, 2000–201914
Overview of ocular toxicities associated with breast cancer therapies14
Correction: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium14
Biomarkers predictive of a response to extended endocrine therapy in breast cancer: a systematic review and meta-analysis14
Letter to the editor regarding “Association between gout and subsequent breast cancer: a retrospective cohort study including 67,598 primary care patients in Germany”14
Re: Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)14
Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients14
Correction: Five-year survival prognosis of young, middle-aged, and elderly adult female invasive breast cancer patients by clinical and lifestyle characteristics14
Aging-accumulated methylmalonic acid serum levels at breast cancer diagnosis are not associated with distant metastases14
Rate of breast biopsy referrals in female BRCA mutation carriers aged 50 years or more: a retrospective comparative study and matched analysis14
A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast13
Burden and trajectory of social needs after breast cancer diagnosis at a safety-net hospital13
Promoting Resilience in Stress Management (PRISM) for women with breast cancer: a qualitative analysis of patient impressions and recommendations13
Breast magnetic resonance imaging patterns of tumor regression after neoadjuvant chemotherapy and immunotherapy in early triple-negative breast cancer patients: prediction of pathological response and13
Neighborhood characteristics and breast tumor methylation: using epigenomics to explore cancer outcome disparities13
PGM5P3-AS1 regulates MAP1LC3C to promote cell ferroptosis and thus inhibiting the malignant progression of triple-negative breast cancer13
BRCA promoter methylation in triple-negative breast cancer is preserved in xenograft models and represents a potential therapeutic marker for PARP inhibitors13
The impact of race and age on response to neoadjuvant therapy and long-term outcomes in Black and White women with early-stage breast cancer13
Association of statin use on survival outcomes of patients with early-stage HER2-positive breast cancer in the APHINITY trial13
High neuroticism is associated with common late adverse effects in a nationwide sample of long-term breast cancer survivors13
Optimizing surgical strategy in locally advanced breast cancer: a comparative analysis between preoperative MRI and postoperative pathology after neoadjuvant chemotherapy13
Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database13
Analysis of data from the PALOMA-3 trial confirms the efficacy of palbociclib and offers alternatives for novel assessment of clinical trials13
Worse survival despite indolent features for triple-negative invasive lobular carcinoma: a Swedish nationwide registry-based study13
Quantifying radiation in the axillary bed at the site of lymphedema surgical prevention13
Single-institution outcomes after excision of benign phyllodes tumors: low recurrence risk even with positive margins13
An overview of genetic services delivery for hereditary breast cancer13
Association of body composition and surgical outcomes in patients with early-stage breast cancer13
Secretory breast carcinoma: a multicenter clinicopathologic study of 80 cases with emphasis on prognostic analysis and chemotherapy benefit13
Long-term survival after sentinel lymph node biopsy or axillary lymph node dissection in pN0 breast cancer patients: a population-based study13
Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study13
Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center13
Pilot study to assess prolonged overnight fasting in breast cancer survivors (longfast)13
Epidemiology of interstitial lung disease in patients with metastatic breast cancer at baseline and after treatment with HER2-directed therapy: a real-world data analysis12
The differences between pure and mixed invasive micropapillary breast cancer: the epithelial–mesenchymal transition molecules and prognosis12
The prognostic value of changes in Ki67 following neoadjuvant chemotherapy in residual triple-negative breast cancer: a Swedish nationwide registry-based study12
Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer12
Endocrine therapy initiation among women with stage I–III invasive, hormone receptor-positive breast cancer from 2001–201612
The COVID-19 pandemic and its effects on follow-up of patients with early breast cancer: A patient survey12
Factors associated with breast cancer detection method in California women: an analysis of California Health Interview Survey data12
Circadian rhythm disrupting behaviours and cancer outcomes in breast cancer survivors: a systematic review12
Clinical utility of MRI in the neoadjuvant management of early-stage breast cancer12
Single-nucleotide polymorphisms and the effectiveness of taxane-based chemotherapy in premenopausal breast cancer: a population-based cohort study in Denmark12
Spectrum of germline pathogenic variants in Brazilian hereditary breast/ovarian cancer cases12
Radiation recall dermatitis induced by abemaciclib with successful rechallenge: a case series and literature review12
Lumpectomy surgery for large ductal carcinoma in situ12
Is axillary web syndrome a risk factor for breast cancer-related lymphedema of the upper extremity? A systematic review and meta-analysis12
Multi-level factors drive use of sentinel lymph node biopsy in older women with early-stage breast cancer12
Suppression of breast cancer metastatic behavior by microRNAs targeting EMT transcription factors. A relevant participation of miR-196a-5p and miR-22-3p in ZEB1 expression12
Adverse effects of scalp cooling for the reduction of chemotherapy-induced alopecia: A systematic review and meta-analysis12
Variant allele frequency in circulating tumor DNA correlated with tumor disease burden and predicted outcomes in patients with advanced breast cancer12
Comparing quality of breast cancer care in the Netherlands and Norway by federated propensity score analytics12
Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique12
Association between body mass index and incidence of breast cancer in premenopausal women: a Japanese nationwide database study12
Diagnostic performance of screening mammography according to menstrual cycle among Asian women12
High-resolution microCT to assess breast microcalcification morphometry by histologic lesion subtype and radiologic classification12
Tumor-associated mononuclear cells in the tumor bed of triple-negative breast cancer associate with clinical outcomes in the post-neoadjuvant chemotherapy setting12
Severe hyponatremia with abemaciclib use in the absence of pre-existing renal disease12
Correction: The novel TP53 3′-end methylation pattern associated with its expression would be a potential biomarker for breast cancer detection12
Aromatase inhibitors and contralateral breast cancer in BRCA mutation carriers12
The importance of SOCS1 − 1478 CA/del polymorphism and expression in breast cancer: a case–control study in the north of Iran12
Racial inequities in second-line treatment and overall survival among patients with metastatic breast cancer12
Organoid models derived from patients with malignant phyllodes tumor of the breast12
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age12
A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1–CDK4 interaction12
Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer12
Limitations of locoregional and distant recurrence analysis after neoadjuvant chemotherapy12
Perceptions of breast cancer risk after breast density notification in a population-based screening program12
Reply to: “Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)”12
Long-term outcomes of dual vs single HER2-directed neoadjuvant therapy in NSABP B-4111
HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series11
Relations between recurrence risk perceptions and fear of cancer recurrence in breast cancer survivors11
Risk of secondary malignancy after radiotherapy for breast cancer: long-term follow-up of Japanese patients with breast cancer11
Is de-escalation of treatment by omission of radiotherapy associated with fear of cancer recurrence in women with early breast cancer? An exploratory study11
Duration and effect of neoadjuvant endocrine therapy on invasive tumor cellularity in hormone receptor-positive breast cancer11
First mammogram-detected cancers portend worse survival in young women diagnosed with breast cancer11
Effect of pretreatment lab abnormalities on the time-to-treatment discontinuation and overall survival of metastatic breast cancer patients receiving CDK 4/6i, PI3Ki, and/or mTORi11
Reply to Bourgeois P.11
Estimating the incidence of breast cancer recurrence using administrative data11
Real-world clinical outcomes of patients with BRCA-mutated, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer: a CancerLinQ® study11
BAFF overexpression in triple-negative breast cancer promotes tumor growth by inducing IL-10-secreting regulatory B cells that suppress anti-tumor T cell responses11
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy11
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients11
Reciprocal regulation of forkhead box C1 and L1 cell adhesion molecule contributes to triple-negative breast cancer progression11
Baseline gut microbiota as a predictive marker for the efficacy of neoadjuvant chemotherapy in patients with early breast cancer: a multicenter prospective cohort study in the Setouchi Breast Project-11
Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center11
Tumor-infiltrating lymphocytes as a predictor of axillary and primary tumor pathological response after neoadjuvant chemotherapy in patients with breast cancer: a retrospective cohort study11
Sexual activity and functioning in long-term breast cancer survivors; exploring associated factors in a nationwide survey11
Indocyanine green angiography guidance for vascular preservation in skin and nipple sparing mastectomy11
Frequent upregulation of HER2 protein in hormone-receptor-positive HER2-negative breast cancer after short-term neoadjuvant endocrine therapy11
Safe perioperative tamoxifen use in autologous breast free flap reconstruction: systematic review and meta-analysis11
Relationship between oily fish intake and breast cancer based on estrogen receptor status: a Mendelian randomization study11
Breast surgery after neoadjuvant chemotherapy in patients with lobular carcinoma: surgical and oncologic outcome11
Clinico–pathologic factors and survival of patients with breast cancer diagnosed with de novo brain metastasis: a national cancer database analysis11
Association between Extract Rheum rhaponticum 731 (ERr 731) prescription and subsequent breast cancer11
Does a brief surgeon training in negotiation theory principles decrease rates of contralateral prophylactic mastectomy?11
Identifying research priorities for improving information and support for patients undergoing breast cancer surgery: a UK patient-centred priority setting project11
Breast cancer and incidence of type 2 diabetes mellitus: a systematic review and meta-analysis11
Radiation therapy for triple-negative breast cancer: emerging role of microRNAs as biomarkers and radiosensitivity modifiers. A systematic review11
Oncologic safety of axillary lymph node dissection with immediate lymphatic reconstruction10
Stalled at the intersection: insurance status and disparities in post-mastectomy breast reconstruction10
COVID-19 related change in breast cancer diagnosis, stage, treatment, and case volume: 2019–202110
Correlation between trophoblast cell-surface antigen-2 (Trop-2) expression and pathological complete response in patients with HER2-positive early breast cancer treated with neoadjuvant docetaxel, car10
The impact of germline BRCA pathogenic variants in locally advanced, triple negative breast cancer treated with platinum-based neoadjuvant chemotherapy10
The association between age at breast cancer diagnosis and prevalence of pathogenic variants10
USP17L2-SIRT7 axis regulates DNA damage repair and chemoresistance in breast cancer cells10
Molecular characterization of ESR1 variants in breast cancer10
Prognostic significance of baseline skeletal muscle index and its dynamics in patients with metastatic breast cancer undergoing eribulin treatment10
Long-term benefits of exercise interventions during chemotherapy in breast cancer: insights from the optitrain trial calling for longitudinal studies10
Association between trajectories of prescription opioid use and risk of opioid use disorder and overdose among US nonmetastatic breast cancer survivors10
Chronic skin toxicities in breast cancer survivors: a systematic review and meta-analysis of radiotherapy techniques10
Impact of analysis of the sentinel lymph node by one-step nucleic acid amplification (OSNA) compared to conventional histopathology on axillary and systemic treatment: data from the Dutch nationwide c10
Postmenopausal overweight and breast cancer risk; results from the KARMA cohort10
Clinical effectiveness and safety of olaparib in BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: final analysis of LUCY10
Impact of exercise on chemotherapy-induced peripheral neuropathy in survivors with post-treatment primary breast cancer10
Higher pre-diagnostic serum syndecan-4 levels are associated with increased breast cancer risk: a case-cohort study10
Synchronous and metachronous bilateral breast cancer among women with a history of lobular carcinoma in situ10
Impact of diabetes on surgery and radiotherapy for breast cancer10
How can we optimize the surgical management of the axilla in breast cancer since the MonarchE trial?10
Standardization of the tumor-stroma ratio scoring method for breast cancer research10
Neoadjuvant systemic therapy in geriatric breast cancer patients: a National Cancer Database (NCDB) analysis10
Oral minoxidil for late alopecia in cancer survivors10
History of infertility and risk of breast cancer: a prospective cohort study10
0.12801384925842